USD10
APMD Shares
About ApnimedApnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
USD10
APMD Shares
About ApnimedApnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$855.43M
OPEN PRICE
$22.00
LOW (1Y)
$16.12
HIGH (1Y)
$29.15
LOW (24H)
$16.12
HIGH (24H)
$29.15
VOLUME (24H)
$3.44M
Price history
Time | Price | Change |
|---|---|---|
Today | $22.00 | |
1 Day | $18.00 | |
1 Week | $17.70 | |
1 Month | $17.70 | |
1 Year | $25.00 |
Past performance is not a reliable indicator of future results.
Discover more
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.